175M is a fair chunk of money (that is more then Achillion's market cap and 2/3 Idenix's)...
If one believes this was money spent to get out of the HCV exclusivity deal with ITMN, then I interpret this as all the more reason to believe that Roche can afford a new partnership with ACHN or IDIX. ; )